Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein
暂无分享,去创建一个
E. Masliah | D. Cribbs | I. Petrushina | M. Blurton-Jones | A. Ghochikyan | H. Davtyan | M. Agadjanyan | A. Hovakimyan | T. Antonyan | G. Chailyan | K. Zagorski | Sepideh Kiani Shabestari
[1] E. Masliah,et al. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies , 2022, npj Vaccines.
[2] F. Rahbarizadeh,et al. A brief review on DNA vaccines in the era of COVID-19 , 2021, Future virology.
[3] H. Chandra,et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India , 2021, EClinicalMedicine.
[4] S. Biswas,et al. Methods to improve the immunogenicity of plasmid DNA vaccines. , 2021, Drug discovery today.
[5] R. Koh,et al. Immunotherapies for Parkinson's disease: Progression of Clinical Development. , 2021, CNS & neurological disorders drug targets.
[6] L. Ferrucci,et al. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.
[7] C. Gravel,et al. Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions , 2020, Journal of Parkinson's disease.
[8] S. Silvestre,et al. Alzheimer's disease: Recent treatment strategies. , 2020, European journal of pharmacology.
[9] D. Weissman,et al. Recent advances in mRNA vaccine technology. , 2020, Current opinion in immunology.
[10] A. Obenaus,et al. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials , 2020, Neurobiology of Disease.
[11] N. Petrovsky,et al. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice , 2019, Alzheimer's Research & Therapy.
[12] N. Petrovsky,et al. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice , 2019, Scientific Reports.
[13] J. Cedarbaum,et al. Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 , 2019, Movement disorders : official journal of the Movement Disorder Society.
[14] H. Nielsen,et al. α-synuclein in the pathophysiology of Alzheimer’s disease , 2019, Molecular Neurodegeneration.
[15] Margaret A. Liu. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies , 2019, Vaccines.
[16] T. Roberts,et al. Genetics, Human Major Histocompatibility Complex (MHC) , 2019 .
[17] O. Iordache,et al. Technologies , 2018, Studies in Systems, Decision and Control.
[18] E. Masliah,et al. MultiTEP platform–based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency , 2017, Neurobiology of Aging.
[19] P. Offit,et al. Plotkin's Vaccines , 2017 .
[20] D. Cribbs,et al. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. , 2017, Vaccine.
[21] D. Cribbs,et al. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] M. Grundman,et al. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.
[23] N. Petrovsky,et al. Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules , 2016, Scientific Reports.
[24] Even Fossum,et al. Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines , 2015, Front. Immunol..
[25] Mary M. Cavanagh,et al. Naive T Cell Maintenance and Function in Human Aging , 2015, The Journal of Immunology.
[26] J. Trojanowski,et al. α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration , 2014, Cell reports.
[27] D. Cribbs,et al. The MultiTEP platform–based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates , 2014, Alzheimer's & Dementia.
[28] D. Cribbs,et al. Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques , 2014, Alzheimer's & Dementia.
[29] D. Cribbs,et al. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: Feasibility study , 2014, Neuroscience Letters.
[30] Susan Lindquist,et al. Mechanisms of protein-folding diseases at a glance , 2014, Disease Models & Mechanisms.
[31] D. Holtzman,et al. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.
[32] D. Holtzman,et al. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.
[33] A. Kiyatkin,et al. Refinement of a DNA based Alzheimer disease epitope vaccine in rabbits , 2013, Human vaccines & immunotherapeutics.
[34] E. Masliah,et al. Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.
[35] J. Trojanowski,et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.
[36] E. Sigurdsson,et al. Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.
[37] E. Masliah,et al. Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.
[38] J. Julien,et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS , 2010, Journal of neurochemistry.
[39] D. Cribbs,et al. DNA prime–protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type mice , 2010, Gene Therapy.
[40] G. Pawelec,et al. Immunity, ageing and cancer , 2008, Immunity & Ageing.
[41] P. Mcgeer,et al. The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease , 2008, Experimental Neurology.
[42] J. Marsh,et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Montefiori,et al. Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting , 1998, Journal of Virology.
[44] R. Coffman,et al. Lymphokine control of in vivo immunoglobulin isotype selection. , 1990, Annual review of immunology.
[45] R. Coffman,et al. Heterogeneity of cytokine secretion patterns and functions of helper T cells. , 1989, Advances in immunology.
[46] R. Fernandez-Botran,et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells , 1988, Nature.
[47] W. Paul,et al. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.
[48] K. Welsh,et al. The human major histocompatibility complex (MHC) , 1984 .
[49] D. Penn,et al. The major histocompatibility complex (MHC). , 1983, Transplantation proceedings.